• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
J Korean Med Sci. 2022 Feb 7;37(5):e32. doi: 10.3346/jkms.2022.37.e32.ABSTRACTDermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this case, we present the case of a 43-year-old Asian Indian female who was diagnosed with DM 10 days after receiving the second dosage of BNT162b2 mRNA COVID-19 vaccination, in the absence of any additional triggering factors. The diagnosis was established...
Source: Journal of Korean Medical Science - February 8, 2022 Category: Biomedical Science Authors: Wesam Gouda Anwar Albasri Faisal Alsaqabi Humoud Y Al Sabah Marwan Alkandari Hassan Abdelnaby Source Type: research

BCG vaccination in health care providers and the protection against COVID-19
A number of coronavirus disease 2019 (COVID-19) vaccine candidates have shown promising results, but substantial uncertainty remains regarding their effectiveness and global rollout. Boosting innate immunity with bacillus Calmette Guérin (BCG) or other live attenuated vaccines may also play a role in the fight against the COVID-19 pandemic. BCG has long been known for its nonspecific beneficial effects that are most likely explained by epigenetic and metabolic reprogramming of innate immune cells, termed trained immunity. In this issue of the JCI, Rivas et al. add to these arguments by showing that BCG-vaccinated health c...
Source: Journal of Clinical Investigation - January 20, 2021 Category: Biomedical Science Authors: Mihai G. Netea, Jos W.M. van der Meer, Reinout van Crevel Source Type: research

BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers
CONCLUSIONS A history of BCG vaccination was associated with a decrease in the seroprevalence of anti–SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19–related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.
Source: Journal of Clinical Investigation - January 20, 2021 Category: Biomedical Science Authors: Magali Noval Rivas, Joseph E. Ebinger, Min Wu, Nancy Sun, Jonathan Braun, Kimia Sobhani, Jennifer E. Van Eyk, Susan Cheng, Moshe Arditi Source Type: research